Atara Biotherapeutics, Inc. 8-K

What Happened
Atara Biotherapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and furnished a press release titled “Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress.” The company filed Form 8-K on May 12, 2026 (Item 2.02) to report results of operations and financial condition; the press release is furnished as Exhibit 99.1. The filing is signed by Yanina Grant-Huerta, Chief Accounting Officer and principal financial and accounting officer.

Key Details

• Filing date: May 12, 2026 (Form 8-K).
• Reporting period: Quarter ended March 31, 2026.
• Disclosure: Item 2.02 — results of operations and financial condition; press release furnished as Exhibit 99.1.
• Administrative: Form 8-K also includes the Inline XBRL cover page (Exhibit 104) and is signed by the company’s Chief Accounting Officer.

Why It Matters
This 8-K signals Atara has publicly released its Q1 2026 quarterly results and operational update; investors should review the furnished press release (Exhibit 99.1) for specific metrics such as revenue, net loss, cash runway, and any program updates. The filing itself does not include detailed financial tables in-line — the press release contains the company’s disclosed figures and commentary that are material for assessing near-term performance and clinical/operational progress.